PathGroup is pleased to announce the release of SmartGenomics™ Complete, a pan cancer assay encompassing 160 cancer related genes, 126 gene fusions and whole genome copy number changes via cytogenomic array.

Also included in this major release are five new solid tumor disease specific profiles for use at diagnosis of various malignancies especially for metastatic, aggressive and/or high grade tumors in the following cancer types: Bladder, Breast, Gynecological (including ovarian carcinoma), Prostate and Sarcoma. Additionally, two new hematologic malignancy profiles have been introduced for myeloid neoplasms and lymphoid neoplasms respectively.

Existing SmartGenomics Profiles have also been improved to include the latest relevant assays such as PDL-1 for NSCLC, Her2 for colorectal cancer, gene fusions for thyroid carcinoma and neurological malignancies, copy number support for melanoma, plus other clinically supported additions. Additional information including the genes of interest, fusion partners and profile breakdowns are available by contacting Oncology Customer Support at OncologySupport@pathgroup.com.

Multiple benefits of high-throughput sequencing (commonly referred to as Next-Generation Sequencing or NGS) include: smaller input DNA requirements, greater sensitivity/specificity, advanced bioinformatics processing and rapid turn-around time.

Click HERE for more information.